Skip to main content
  •   

    ROCK Inhibitors: Targeting Trabecular Outflow

    By Ruth D. Williams, MD; Joel S. Schuman, MD, FACS
    Glaucoma 360
    03:15
    Glaucoma, IOP and Aqueous Flow, Medical Therapy
    Add to My Bookmarks

    In this interview, Dr. Joel Schuman introduces ROCK inhibitors, a new class of drugs that lower IOP by inhibiting Rho-kinase (ROCK) and thus increase outflow through the trabecular meshwork. Because ROCK inhibitors and prostoglandins act through unique pathways, Dr. Schuman believes drugs from each class can be used in concert to an additive effect. Several ROCK inhibitors, including ROCK/NET which also limits norepinephrine transporter (NET), are primed to enter late-phase clinical trials.